Apr 15, 2024 · Here we report that nerve growth factor receptor (NGFR) is upregulated in skeletal cells during OA and plays an essential role in the remodeling and repair of osteoarthritic joints.

Nov 20, 2020 · Chronic pain from osteoarthritis (OA) is highly prevalent, and effective non-opioid medications are few. Nerve growth factor (NGF) is an important neurotrophin that activates nociceptive...

In this review, we present the role of nerve growth factor (NGF) in pain generation, relationship between NGF and OA pain, and pathogenic factors (interleukin-1β, transforming growth factor-β1, mechanical loading, and adipokines) involved in OA development.

In this regard, antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents in development for the treatment of chronic pain conditions such as osteoarthritis and chronic low-back pain.

Jul 26, 2021 · Associations between anti-NGF antibody therapy and rapidly progressive OA have prompted research into alternative approaches to target NGF that have improved safety profiles. A new study published...

Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain.

Here we report that nerve growth factor receptor (NGFR) is upregulated in skeletal cells during OA and plays an essential role in the remodeling and repair of osteoarthritic joints.

Levels of endogenous nerve growth factor (NGF) are increased in osteoarthritic (OA) joints in patients and animal models and may be an important cause of pain associated with OA. NGF binds to the high-affinity tropomyosin kinase A (Trk A) and low affinity p75 receptors.

In this regard, antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents in development for the treatment of chronic pain conditions such as osteoarthritis and chronic low-back pain.

Feb 22, 2021 · Nerve growth factor (NGF), another nociceptor sensitising agent, is consequently being investigated as an alternative potential therapeutic target for the treatment of OA pain. During embryogenesis, NGF drives the growth and differentiation of sensory and sympathetic ganglia but becomes a sensitizing agent in the postnatal period.

Aug 1, 2017 · In this review, we present the role of nerve growth factor (NGF) in pain generation, relationship between NGF and OA pain, and pathogenic factors (interleukin-1β, transforming growth factor-β1, mechanical loading, and adipokines) involved in OA development.

Nerve growth factor (NGF) is a promising analgesic target, particularly in osteoarthritis (OA) where existing therapies are inadequate. We hypothesised that pain responses to NGF are increased in OA joints.

Jan 20, 2014 · Several lines of evidence highlight NGF as an attractive therapeutic target to control OA pain. NGF is a key factor in inflammation-associated hyperalgesia, whose protein is detected in OA synovial fluid and mRNA expression is enhanced in OA chondrocytes. NGF may also mediate joint damage.

Jul 4, 2019 · The anti-nerve growth factor (NGF) antibody fasinumab improved pain and function in patients with osteoarthritis (OA) in a phase III study in the USA. 342 patients with knee or hip OA were...

Nerve growth factor (NGF) and sensory nerves are key factors in established osteoarthritis (OA) knee pain. We investigated the time course of NGF expression and sensory nerve growth across early and late stages of OA progression in rat knees.

Apr 25, 2022 · Background: The efficacy and safety of anti-nerve growth factor (NGF) antibody therapy used for osteoarthritis (OA) pain are controversial. Purpose: To evaluate the efficacy and safety of anti-NGF antibody therapy via a meta-analysis of randomized controlled trials (RCTs).

This systematic review aimed to evaluate the efficacy and safety of anti-nerve growth factor (NGF) monoclonal antibodies vs active comparator therapy, such as NSAIDs and oxycodone, in treating hip or knee OA.

NGF inhibitors reduce pain and improve physical function in patients with moderate to severe hip or knee OA. The anti-NGF antibodies currently under development are administered by subcutaneous injection every 4 weeks to 8 weeks, providing a prolonged duration of pain relief.

Nerve growth factor (NGF) functions to modulate osteoarthritis (OA)‐associated pain. Although recent studies suggest that tumour necrosis factor (TNF)‐α and interleukin (IL)‐1β mediate NGF activity in human synovial fibroblasts, the regulation of ...

Nerve growth factor (NGF) functions to modulate osteoarthritis (OA)-associated pain. Although recent studies suggest that tumour necrosis factor (TNF)-α and interleukin (IL)-1β mediate NGF activity in human synovial fibroblasts, the regulation of NGF expression in human synovial macrophages remains …